Biotech IPOs Return 55% in 2026 as US Listings Overall Lose 4.4%
Updated
Updated · Bloomberg · Jul 21
Biotech IPOs Return 55% in 2026 as US Listings Overall Lose 4.4%
3 articles · Updated · Bloomberg · Jul 21
Summary
Biotech and pharmaceutical IPOs in the US have delivered a 55% weighted average return in 2026, making them the standout performers in this year’s new-issue market.
Bloomberg-compiled data show that surge sharply outpaces the broader US IPO market, which is down 4.4% on a weighted average basis after excluding SPACs and other financial vehicles.
The sector has also overtaken artificial-intelligence-related listings as the market’s strongest pocket, shifting attention away from one of the hottest recent themes.
That performance is helping biotech steal the IPO spotlight as bankers prepare a steady pipeline of summer debuts.